• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vaxchora (Cholera Vaccine, Live, Oral)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vaxchora (Cholera Vaccine, Live, Oral)

  • Profile

Profile

Contact Information

Contact: Emergent BioSolutions
Website: http://www.vaxchora.com/

Currently Enrolling Trials

    Show More

    General Information

    Vaxchora contains live attenuated cholera bacteria that replicate in the gastrointestinal tract of the recipient. 

    Vaxchora is specifically approved for active immunization against disease caused by Vibrio cholerae serogroup O1. Vaxchora is approved for use in adults 18 through 64 years of age traveling to cholera-affected areas.

    Mechanism of Action

    Vaxchora contains live attenuated cholera bacteria that replicate in the gastrointestinal tract of the recipient. Immune mechanisms conferring protection against cholera following receipt of Vaxchora have not been determined. However, rises in serum vibriocidal antibody 10 days after vaccination with Vaxchora were associated with protection in a human challenge study.

    Side Effects

    Adverse effects associated with the use of Vaxchora may include, but are not limited to, the following:

    • tiredness
    • headache
    • abdominal pain
    • nausea/vomiting
    • lack of appetite
    • diarrhea

    Dosing/Administration

    Vaxchora is supplied as a suspension for oral administration. After preparation, a single dose of Vaxchora is 100 mL. Vaxchora should be administered a minimum of 10 days before potential exposure to cholera.

    Clinical Trial Results

    The FDA approval of Vaxchora was based on the following trials:

    Vaxchora’s efficacy was demonstrated in a randomized, placebo-controlled human challenge study of 197 subjects in the United States from 18 through 45 years of age. Of the 197 subjects, 68 received Vaxchora and 66 received placebo. The subjects were challenged by oral ingestion of Vibrio cholerae, the bacterium that causes cholera. Vaxchora efficacy was 90 percent among those challenged 10 days after vaccination and 80 percent among those challenged three months after vaccination.  The study included provisions for administration of antibiotics and fluid replacement in symptomatic participants. To prevent transmission of cholera into the community, the study included provisions for administration of antibiotics to subjects not developing symptoms.

    Two placebo-controlled studies to assess the immune system’s response to the vaccine were also conducted in the United States and Australia in adults 18 through 64 years of age. In the 18 through 45 years of age group, 93 percent of Vaxchora recipients produced antibodies indicative of protection against cholera. In the 46 through 64 years of age group, 90 percent produced antibodies indicative of protection against cholera. The effectiveness of Vaxchora has not been established in persons living in cholera-affected areas.

     

    Approval Date: 2016-06-01
    Company Name: PaxVax
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing